In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.
Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...
Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...
Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...
Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...
Investor's Business Daily on MSN
Alumis stock catapults more than 95% as biotech takes on J&J, Protagonist in psoriasis
Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...
CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...
With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026. FDA approval could add to the pressure on Sotyktu, which generated $206 ...
Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...
NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback